Our Approach

our approach

Our advisory work starts from a position of respect
for our clients' organization, people,
products and science.


our approach

We have devoted our careers to the life
sciences industry and have the deepest respect
and admiration for the participants in it.


our approach

We are a very active advisor in the market.
Torreya Partners has successfully closed over
100 assignments since our founding in 2007.

Our Perspective

our approach

We often take an operating perspective
to strategic and transaction work.

Ventrus Biosciences

Merger with Assembly Pharmaceuticals

May 2014

North America

Chelsea Therapeutics

Sale to Lundbeck

Up to $658 million

May 2014

North America


Sale to Shire

$75 million upfront + milestones

May 2014

Asia, Africa, Middle East, Latin America

October 6-8, 2014

AdvaMed - Advanced Medical Technology Association - The MedTech Conference

Chicago, IL

October 27-29, 2014

BioNetwork 2014

Laguna Niguel, CA

November 3-5, 2014

BIO-Europe 2014

Frankfurt, Germany

May 19, 2014

Ventrus Biosciences to Merge With Assembly Pharmaceuticals


May 8, 2014

Lundbeck to acquire Chelsea Therapeutics


May 2, 2014

Fibrotech acquired by Shire for US$75M plus milestones